MedPath

Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy

Phase 3
Recruiting
Conditions
Contrast induced nephropathy.
Other complications following infusion, transfusion and therapeutic injection
T80.8
Registration Number
IRCT20180417039347N1
Lead Sponsor
Zahedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
250
Inclusion Criteria

Eligible patients include individuals older than 21 years old
abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) =1.1 mg/dL)
Undergoing elective cardiac catheterization with or without PCI

Exclusion Criteria

Patients with end-stage renal failure (glomerular filtration rate (GFR) = 15 mL/min),
history of previous dialysis
pulmonary edema
emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ),
exposure to contrast within previous two days ago before procedure
allergies to contrast media,
contraindication to statins
liver disease

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum creatinine level altration. Timepoint: Serum creatinine levels are measured on the first day (day before the procedure) and 48 hours after exposure. Method of measurement: creatinine test.
Secondary Outcome Measures
NameTimeMethod
Incidence of CIN. Timepoint: 48 h post exposure contrast media. Method of measurement: creatinine test.
© Copyright 2025. All Rights Reserved by MedPath